OMEROS CORP (OMER) Stock News

NASDAQ:OMER - Nasdaq - US6821431029 - Common Stock - Currency: USD

3.61 -0.26 (-6.72%)

After market: 3.56 -0.05 (-1.39%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

OMER Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: ACCESS Newswire

D. Boral Capital Acted as Exclusive Placement Agent to Omeros Corporation (Nasdaq: OMER) in Connection with its $22,000,000 Registered Direct Offering

7 days ago - By: Omeros Corporation

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

3 months ago - By: Benzinga

Examining the Future: Omeros's Earnings Outlook

a month ago - By: Omeros Corporation

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

a month ago - By: Omeros Corporation

Omeros Announces Webcast Details for Annual Meeting of Shareholders

2 months ago - By: Benzinga

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

3 months ago - By: Omeros Corporation

Omeros Corporation Reports First Quarter 2025 Financial Results

3 months ago - By: Omeros Corporation

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

3 months ago - By: Omeros Corporation

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

3 months ago - By: Omeros Corporation

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

4 months ago - By: Omeros Corporation

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program

4 months ago - By: Omeros Corporation

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

4 months ago - By: Omeros Corporation

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

4 months ago - By: Omeros Corporation

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

4 months ago - By: Omeros Corporation

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

5 months ago - By: Omeros Corporation

Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder

5 months ago - By: Omeros Corporation

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA